Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wiseman

Showing results (371-380 of 392) with videos related to

Pageof 40
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Journal of Alzheimer'S Disease : JAD|February 6, 2023
PSA-NCAM Regulatory Gene Expression Changes in the Alzheimer's Disease Entorhinal Cortex Revealed with Multiplexed in situ HybridizationBlake Highet, James A Wiseman, Hannah Mein, et al.
Blood|June 16, 2011
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaIvana N M Micallef, Matthew J Maurer, Gregory A Wiseman, et al.
Expert Review of Gastroenterology & Hepatology|June 4, 2020
The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective studyMohamed A Abdallah, Nicha Wongjarupong, Mohamed A Hassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Critical Reviews in Oncology/Hematology|June 22, 2001
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaG A Wiseman, C A White, R B Sparks, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 16, 2004
A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegenerationDavid E Sleat, Jennifer A Wiseman, Mukarram El-Banna, et al.
Pageof 40

Showing results (371-380 of 392) with videos related to

Sort By:
Pageof 40
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Journal of Alzheimer'S Disease : JAD|February 6, 2023
PSA-NCAM Regulatory Gene Expression Changes in the Alzheimer's Disease Entorhinal Cortex Revealed with Multiplexed in situ HybridizationBlake Highet, James A Wiseman, Hannah Mein, et al.
Blood|June 16, 2011
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaIvana N M Micallef, Matthew J Maurer, Gregory A Wiseman, et al.
Expert Review of Gastroenterology & Hepatology|June 4, 2020
The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective studyMohamed A Abdallah, Nicha Wongjarupong, Mohamed A Hassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Critical Reviews in Oncology/Hematology|June 22, 2001
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaG A Wiseman, C A White, R B Sparks, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 16, 2004
A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegenerationDavid E Sleat, Jennifer A Wiseman, Mukarram El-Banna, et al.
Pageof 40